focus -WSS

focus

author：knowledge 2025-09-07 06:40:14 - browse：42

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Even great ERs can’t make up for American health disparities

WSS

Can U.S. cancer drug shortages be fixed?

Meadows told special counsel he could not recall Trump ever declassifying Mar

People can get long Covid without testing positive for virus: Study

Covid misinformation case heads to Supreme Court

Roche's accidental data boosts hopes for anti

California store owner shot dead in dispute over displaying Pride flag: Police

hotspot

focus

knowledge

In age of alternative facts, a scholarly course on calling out crap

Commercial surrogacy can be ethical, despite pope’s claims

What does generative AI mean for health care? We asked experts

Former Pear Therapeutics executives start new VC firm

The cancer drug shortage isn’t new — and neither are the solutions

Medicare drug price negotiation’s day in court

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How the drug

Medicare details structure of new drug price negotiation program

SAMSHA loosens regulations on methadone treatment centers

Wikipedia

Biden administration opens offers in Medicare drug price negotiations

Health officials lay out plans to cope with respiratory virus season

Do digital therapeutics have a future in medicine?

General Catalyst, Summa Health deal will turn on physician buy

Intellia plays down concerns on accidental germline transmission

How to make over

hotspot

explore

entertainment

explore